On June 16, 2020, Kaleido Biosciences, Inc. announced that Alison Lawton has resigned as the Company's Chief Executive Officer (CEO") effective June 16, 2020 to return to the United Kingdom and attend to an unexpected family health matter. Ms. Lawton informed the Board of Directors of her decision on June 14, 2020. Ms. Lawton will continue to serve as a Director and special advisory to the Company and will support the Company through this transition. The Board of Directors has established an Office of the CEO to manage the company through the transition, with Mike Bonney, Executive Chair, to lead the office and Alison Lawton to serve as a special advisor.